What's the latest in tech research in Houston? Here are three revolutionary research projects happening right under our noses. Getty Images

Tons of research happens daily at various Houston institutions — from life-saving medical developments to high tech innovations that will affect the greater business community.

In this Houston research roundup, three research projects from three Houston organizations are set to revolutionize their respective industries.

University of Houston researcher explores potential disruption in blockchain

blockchain

Getty Images

A huge technology question mark within business has been blockchain — how it'll affect the sharing of information and industry as a whole. But, one University of Houston professor and his Texas A&M University colleagues are looking into that potential disruption in a recent paper.

"It's an emerging technology. It's evolving," says Weidong "Larry" Shi, associate professor of computer science at UH, in a UH news release.

Funded by the Borders, Trade, and Immigration Institute, the research has developed into the paper, which was published in the International Journal of Production Research.

A key focus of the research is how blockchain will affect cargo entering the United States, and identifies six pain points within adapting blockchain for cargo management: traceability, dispute resolution, cargo integrity and security, supply chain digitalization, compliance, and trust and stakeholder management, according to the release.

"The wide adoption of blockchain technology in the global SC (supply chain) market is still in its infancy," the article reads. "Industry experts project that on average, it may take about six years for the widespread adoption of blockchain."

Blockchain has the potential to prevent fraud within the global supply chain, among other things.

"The data can't be changed. Everyone (along the supply chain) has a copy. You can add information, but you can't change it," Shi says in the release.

The U.S. Army taps Rice University for network research

Photo by Jeff Fitlow/Rice University

Rice University and the U.S. Army have joined forces for a five-year, $30 million research agreement to modernize the Army — specifically for developing next-generation wireless networks and radio frequency (RF) electronics.

"[The Army Research Laboratory] and Rice will match the right people and capabilities to meet specific challenges, and the cooperative agreement is structured to allow the Army to partner widely across our campus," says Yousif Shamoo, Rice's vice president of research and lead on the ARL partnership, in a recent news release. "One exciting aspect of this partnership is the broader societal benefits. The technologies we're starting with are needed for Army modernization and they could also benefit millions of Americans in communities that still lack high-speed internet."

Without going into too much detail, the two entities are working to advance the Army's existing infrastructure to create networks that can sense attacks and protect themselves by adaption or stealth. The technology has the potential to affect the Army as well as civilians, says Heidi Maupin, the lead ARL contact for the Rice partnership.

"We want to deliver the capability of quickly deploying secure, robust Army communications networks wherever and whenever they're needed," Maupin says in the release. "The technology needed for that will benefit the world by transforming the economics of rural broadband, reducing response times to natural disasters, opening new opportunities for online education and more."

Research out of Baylor College of Medicine advancing information known about vision

Photo via bcm.edu

For humans, seeing is pretty simple — just open your eyes. But the process our eyes go through extremely complex, and scientists have had a hard time recreating the process — until now.

Researchers at Baylor College of Medicine in Houston and the University of Tübingen in Germany have developed a novel computational approach that accelerates the brain's ability to identify optimal stimuli. The complete study by the scientists was published in the journal Nature Neuroscience.

"We want to understand how vision works," says senior author Dr. Andreas Tolias, professor and Brown Foundation Endowed Chair of Neuroscience at Baylor. "We approached this study by developing an artificial neural network that predicts the neural activity produced when an animal looks at images. If we can build such an avatar of the visual system, we can perform essentially unlimited experiments on it. Then we can go back and test in real brains with a method we named 'inception loops."

To track neurons and how they work, the researchers tracked brain activity scanning thousands of images.

"Experimenting with these networks revealed some aspects of vision we didn't expect," says Tolias, founder and director of the Center for Neuroscience and Artificial Intelligence at Baylor, in a release. "For instance, we found that the optimal stimulus for some neurons in the early stages of processing in the neocortex were checkerboards, or sharp corners as opposed to simple edges which is what we would have expected according to the current dogma in the field."

The research is ongoing and will only continue to help dissect how the brain sees and interprets visual elements.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”